Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOXIL/CAELYX plus VELCADE vs VELCADE in Relapsed Multiple Myeloma
NCT00103506Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2004
- Primary completion
- May 2014
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of pegylated liposomal doxorubicin in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Time to Progression. Started Dec 2004; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00103506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00103506.